# Efficacy and Safety of 3 Doses of HL10 Given at Fixed Time Intervals Compared to Standard Therapy

> **NCT00742482** · PHASE3 · TERMINATED · sponsor: **LEO Pharma** · enrollment: 418 (actual)

## Conditions studied

- Acute Lung Injury
- Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** HL 10

## Key facts

- **NCT ID:** NCT00742482
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-01
- **Primary completion:** 2005-01
- **Final completion:** 2005-06
- **Target enrollment:** 418 (ACTUAL)
- **Why stopped:** A 300 patient safety analysis by the Data Monitoring Committee showed a trend towards higher mortality in the treatment group.
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00742482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00742482, "Efficacy and Safety of 3 Doses of HL10 Given at Fixed Time Intervals Compared to Standard Therapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00742482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*